PPP2R1B

Across TCGA pan-cancer cohorts, PPP2R1B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PPP2R1B data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PPP2R1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PPP2R1B expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

CESC, LIHC, and UCEC are the cancer types where PPP2R1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.053	0.786	<.001	36	view →
LIHC	OS	Median	All	0.150	0.786	<.001	21	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	All	1.000	0.503	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PPP2R1B–CESC (DFS)

Open the CESC breakdown →